- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07775924
A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus (ELIPSI)
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-range Study to Assess the Efficacy and Safety of GIA632 in Participants With Moderate to Severe Cutaneous Lichen Planus, Followed by an Extension Period
This study will evaluate the safety and efficacy of GIA632 in participants with moderate to severe cutaneous lichen planus (cLP).
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The main purpose of this study is to investigate the safety and efficacy of GIA632 in participants with moderate to severe cutaneous lichen planus (cLP) across a range of dosing regimens and to identify the optimal dosing regimen to be promoted into the confirmatory Phase 3 program.
This study consists of a screening period (up to 4 weeks), a core treatment period (16 weeks double-blind), an extension period (52 weeks), and a safety follow-up period (12 weeks).
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Novartis Pharmaceuticals
- Telefonnummer: 1-888-669-6682
- E-post: novartis.email@novartis.com
Studer Kontakt Backup
- Navn: Novartis Pharmaceuticals
- Telefonnummer: +41613241111
- E-post: novartis.email@novartis.com
Studiesteder
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2010
- Rekruttering
- Novartis Investigative Site
-
Waitara, New South Wales, Australia, 2077
- Rekruttering
- Novartis Investigative Site
-
-
Victoria
-
Melbourne, Victoria, Australia, 3000
- Rekruttering
- Novartis Investigative Site
-
-
-
-
Ontario
-
London, Ontario, Canada, N6H 5L5
- Rekruttering
- Novartis Investigative Site
-
Toronto, Ontario, Canada, M5A 3R6
- Rekruttering
- Novartis Investigative Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35244
- Rekruttering
- Cahaba Derm and skin hlth ctr 27
-
Hovedetterforsker:
- Vlada Groysman
-
Ta kontakt med:
- Wes Booth
- Telefonnummer: +1 205 778 1564
- E-post: wbooth@cahabaderm.com
-
-
California
-
Fountain Valley, California, Forente stater, 92708
- Rekruttering
- First OC Dermatology
-
Hovedetterforsker:
- Vivian Laquer
-
Ta kontakt med:
- Keiry Espinoza
- Telefonnummer: +1 714 531 2966
- E-post: kespinoza@dermcaremgt.com
-
-
Florida
-
Hollywood, Florida, Forente stater, 33024
- Rekruttering
- Encore Medical Research
-
Hovedetterforsker:
- Jerome Obed
-
Ta kontakt med:
- Yeniska Hall
- Telefonnummer: +1 954 400 1725
- E-post: yhall@encoremedicalresearch.com
-
Miami, Florida, Forente stater, 33173
- Rekruttering
- Miami Derm and Laser Institute
-
Hovedetterforsker:
- Jill Waibel
-
Ta kontakt med:
- Swanee Cepero
- Telefonnummer: +1 305 279 6060
- E-post: swaneec@miamidermlaser.com
-
St. Petersburg, Florida, Forente stater, 33714
- Rekruttering
- Global Clinical Professionals
-
Hovedetterforsker:
- Wanda M Boote
-
Ta kontakt med:
- Nailis Echevarria
- Telefonnummer: +1 727 520 1427
- E-post: nechevarria@researchgcp.com
-
-
Georgia
-
Macon, Georgia, Forente stater, 31217
- Rekruttering
- Skin Care Physicians Of Georgia
-
Ta kontakt med:
- Jennifer Smith
- E-post: jlee@scpog.com
-
Hovedetterforsker:
- David J Cohen
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46256
- Rekruttering
- Dawes Fretzin Clinical Rea Group
-
Hovedetterforsker:
- Kenneth Dawes
-
Ta kontakt med:
- Megan Kirchner
- Telefonnummer: +1 317 516 5030#102
- E-post: mkirchner@ecommunity.com
-
-
Kansas
-
Overland Park, Kansas, Forente stater, 66213
- Rekruttering
- Essential Medical Research
-
Ta kontakt med:
- Reena Nagavelli
- Telefonnummer: 19186451992
- E-post: ReenaN@emedr.com
-
Hovedetterforsker:
- Meena Singh
-
-
Louisiana
-
Baton Rouge, Louisiana, Forente stater, 70809
- Rekruttering
- Louisiana Dermatology Associates
-
Hovedetterforsker:
- Ira Thorla
-
Ta kontakt med:
- Hilary Kingsley
- Telefonnummer: +1 225 927 5663
- E-post: hkingsley@delricht.com
-
New Orleans, Louisiana, Forente stater, 70115
- Rekruttering
- Delricht Research
-
Hovedetterforsker:
- Deirdre Hooper
-
Ta kontakt med:
- Emily Krambeck
- Telefonnummer: +1 504 336 2667
- E-post: ekrambeck@delricht.com
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- Rekruttering
- Uni Of Michigan Health System
-
Ta kontakt med:
- Hyein Kim
- Telefonnummer: +1 734 936 5504
- E-post: kihyein@med.umich.edu
-
Hovedetterforsker:
- Mio Nakamura
-
Fort Gratiot, Michigan, Forente stater, 48059
- Rekruttering
- Hamzavi Dermatology
-
Hovedetterforsker:
- Iltefat Hamzavi
-
Ta kontakt med:
- Brynn Bemis
- Telefonnummer: +1 810 455 1600
- E-post: bbemis@hamzavi.com
-
-
Minnesota
-
New Brighton, Minnesota, Forente stater, 55112
- Rekruttering
- Minnesota Clinical Study Center
-
Ta kontakt med:
- Madeline Thompson
- Telefonnummer: +1 763 576 9312
- E-post: mthompson@associatedskincare.com
-
Hovedetterforsker:
- Steven E Kempers
-
-
Missouri
-
Saint Joseph, Missouri, Forente stater, 64506
- Rekruttering
- MediSearch Clinical Trials
-
Ta kontakt med:
- Heather Jackson
- Telefonnummer: 816 364 1515
- E-post: heather.jackson@medisearchderma.com
-
Hovedetterforsker:
- Melody Stone
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68144
- Rekruttering
- Skin Specialists PC
-
Hovedetterforsker:
- Joel Schlessinger
-
Ta kontakt med:
- Carrie Hill
- Telefonnummer: +1 402 334 7546
- E-post: carrie@lovelyskin.com
-
-
Texas
-
Bellaire, Texas, Forente stater, 77401
- Rekruttering
- Bellaire Dermatology Associates
-
Hovedetterforsker:
- Craig F Teller
-
Ta kontakt med:
- Hannah Green
- Telefonnummer: +1 713 661 4383
- E-post: hannah.green@bellairedermatology.com
-
Mansfield, Texas, Forente stater, 76063
- Rekruttering
- NextGen Clinical Research and Innovation Inc-Network
-
Hovedetterforsker:
- Jeannine Hoang
-
Ta kontakt med:
- Lakkureddi Alagarsamy
- E-post: LakkureddiA@NextGenClinical.Us
-
Pflugerville, Texas, Forente stater, 78660
- Rekruttering
- Austin Inst for Clinical Research
-
Hovedetterforsker:
- Edward Lain
-
Ta kontakt med:
- Dominique Talamantes
- Telefonnummer: +1 512 279 2545
- E-post: d.talamantes@atxresearch.com
-
San Antonio, Texas, Forente stater, 78213
- Rekruttering
- RFSA Dermatology
-
Hovedetterforsker:
- Lindsey Finklea
-
Ta kontakt med:
- Jonathan Joseph
- E-post: jonathanj.rfsadermatology@gmail.com
-
-
-
-
-
Beijing, Kina, 100050
- Rekruttering
- Novartis Investigative Site
-
Shanghai, Kina, 200040
- Rekruttering
- Novartis Investigative Site
-
Tianjin, Kina, 300052
- Rekruttering
- Novartis Investigative Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
- Male or female (as assigned at birth) participants ≥ 18 years of age at the time of screening.
- Individuals with a diagnosis of cLP, confirmed
- histologically by a skin biopsy (either historically within 1 year prior to screening or at screening if historical one not available), and
- by physical examination by the investigator at screening.
- Moderate to severe cLP
- Two or more body regions affected (any two or more of the following: head and neck, trunk, upper extremities including hands, lower extremities including feet).
- Diagnosis of cLP inadequately controlled by at least one topical treatment for at least 3 months (either via continuous use or burst and taper regimen), or such treatment being considered not advisable, as per investigator judgement, assessed at screening.
Topical treatment includes, but is not limited to, topical corticosteroids, topical calcineurin inhibitors, topical cholecalciferol analogues, topical PDE4 inhibitors, topical JAK inhibitors, and topical aryl hydrocarbon receptor agonists.
Key Exclusion Criteria:
- Individuals unable or unwilling to follow the study procedures, handle the electronic diary (eDiary), and/or to complete the study-related questionnaires.
- Diagnosis of drug-induced lichen planus (lichenoid drug eruption) or lichen planus pigmentosus.
- Presence of skin conditions that may interfere with study assessments, including histologic findings in the biopsy, as assessed at screening and baseline.
- Previous exposure to biologic drugs directly targeting IL-15 or any subunit of the IL-15 receptor.
- Use of prohibited medication and treatments.
Other protocol-defined inclusion/exclusion criteria may apply.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebo
Participants will receive matching placebo according to the treatment regimen assigned at randomization during the study treatment period. |
Matching placebo GIA632 administered according to the assigned study treatment regimen. |
|
Eksperimentell: GIA632 - Treatment regimen 1
Participants will receive GIA632 according to the treatment regimen assigned at randomization during the study treatment period. |
GIA632 administered according to the assigned study treatment regimen. |
|
Eksperimentell: GIA632 - Treatment regimen 2
Participants will receive GIA632 according to the treatment regimen assigned at randomization during the study treatment period. |
GIA632 administered according to the assigned study treatment regimen. |
|
Eksperimentell: GIA632 - Treatment regimen 3
Participants will receive GIA632 according to the treatment regimen assigned at randomization during the study treatment period. |
GIA632 administered according to the assigned study treatment regimen. |
|
Eksperimentell: GIA632 - Treatment regimen 4
Participants will receive GIA632 according to the treatment regimen assigned at randomization during the study treatment period. |
GIA632 administered according to the assigned study treatment regimen. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants achieving an Investigator Global Assessment (IGA) response
Tidsramme: Week 16
|
IGA response is defined as an Investigator Global Assessment score of 0 (clear) or 1 (almost clear). The IGA is measured on a 5-point scale ranging from 0 to 4, where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. |
Week 16
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Absolute change from baseline in weekly mean daily Peak Pruritus Numerical Rating Scale (PP-NRS) score
Tidsramme: Baseline and Week 16
|
The Peak Pruritus Numerical Rating Scale (PP-NRS) is used to assess participant-reported intensity of worst itch during the previous 24 hours. Participants rate their worst itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). |
Baseline and Week 16
|
|
Number of participants achieving an IGA score of Clear (0) or Almost Clear (1)
Tidsramme: Weeks 4, 8, and 12
|
The IGA is measured on a 5-point scale ranging from 0 to 4, where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. |
Weeks 4, 8, and 12
|
|
Number of participants achieving a ≥2-Point improvement from baseline in IGA score
Tidsramme: Baseline, Weeks 4, 8, 12, and 16
|
The IGA is measured on a 5-point scale ranging from 0 to 4, where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. |
Baseline, Weeks 4, 8, 12, and 16
|
|
Absolute change from baseline in Lichen Planus Activity and Damage Index (LiPADI) Activity score
Tidsramme: Baseline, Weeks 4, 8, 12, and 16
|
The Lichen Planus Activity and Damage Index (LiPADI) is a clinical assessment tool used to evaluate the severity and extent of lichen planus. The activity score assesses active inflammation based on morphologic features including erythema, hypertrophy, and scaling. |
Baseline, Weeks 4, 8, 12, and 16
|
|
Absolute Change From Baseline in Lichen Planus Activity and Damage Index (LiPADI) Damage Score
Tidsramme: Baseline, Weeks 4, 8, 12, and 16
|
The Lichen Planus Activity and Damage Index (LiPADI) is a clinical assessment tool used to evaluate the severity and extent of lichen planus. The damage score assesses disease-related damage based on morphologic features including hyperpigmentation and scarring/atrophy. |
Baseline, Weeks 4, 8, 12, and 16
|
|
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: Up to 80 weeks
|
Number of participants with AEs and SAEs, including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs. |
Up to 80 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CGIA632C12201
- 2025-522300-25-00 (Annen identifikator: EU CTIS)
- 2025 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .